Biotech Values

[spartex]

Biodel

http://www.biodel.com/about/overview.htm

The PIII trials are for a rapid-acting injectable insulin that (their angle) may work faster in a person's body than the leading Humalog insulin. fyi, I use Humalog and it usually works within 20-30 min which is good for me. I guess once could say if you can eat 10 min after a shot that is even "better". But it leaves you little time to shoot up and eat. In other words, you would probably start your meal right after taking your shot. The key is that they can compete in a $2 bil/year+ market for fast-acting insulins.

Their other product in PI is for a oral tablet formulation of insulin. "Biodel is also conducting a Phase I clinical trial evaluating VIAtab™, an oral (sublingual) tablet formulation of insulin." This one I believe would really have the killer advantage if it works and was approved. It would allow diabetics to take their insulin using a tablet rather than shots, or the inconvenient Eruba bong inhalent. May even compete with the slower acting insulins. I need to study this company further to find out how much of a market advantage it may have as well as its competitors.